Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Son, Keum Joo ^a   Choi, Ki Ryung ^a   Ryu, Chung Kyu ^b   Lee, Seog Jae ^c   Kim, Ho Jeong ^b   Lee, Hyunah ^a  

^a Pharmicell Co Ltd   (South Korea)

^b Ewha Womans University   (South Korea)

^c Jeju National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CALRETICULIN; CHAPERONIN 60; DOXORUBICIN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HETEROCYCLIC COMPOUND; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; PROTEINASE; QUINONE DERIVATIVE; R 2016; STAT3 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 6; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; CELL ADHESION MOLECULE; CYTOKINE; HEAT SHOCK PROTEIN; R2016;

ANGPT1 GENE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL COUNT; CELL DEATH; CELL SURFACE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; DRUG CYTOTOXICITY; FEMALE; FGF7 GENE; GENE; GENETIC TRANSCRIPTION; IMMUNOGENICITY; LUNG CANCER CELL LINE; MELANOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; UPREGULATION; URGCP GENE; ANIMAL; C57BL MOUSE; CHEMISTRY; COCULTURE; CYTOLOGY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; NECROSIS; NEOPLASMS; PATHOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD11C; APOPTOSIS; CALRETICULIN; CARBAZOLES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAT-SHOCK PROTEINS; HETEROCYCLIC COMPOUNDS; MICE; MICE, INBRED C57BL; NECROSIS; NEOPLASMS; QUINONES; UP-REGULATION;

EID: 85015325987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173121     Document Type: Article

References (24)

1. Oh SJ, Ryu CK, Back SY, Lee H. Cellular mechanism of newly synthesized indoledione derivativeinduced immunological death of tumor cell. Immune Netw. 2011 Dec; 11(6): 383-389. doi: 10.4110/in.2011.11.6.383 PMID: 22346779
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29; 313(5795): 1960-1964. doi: 10.1126/science.1129139 PMID: 17008531
3. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015 Mar 2; 4(4).
4. Wong DY, Ong WW, Ang WH. Induction of immunogenic cell death by chemotherapeutic plantinum complexes. Angew Chem Int Ed Engl. 2015 May 26; 54(22): 6483-6487. doi: 10.1002/anie.201500934 PMID: 25873535
5. Cirone M, Livia DR, Lavinia V. L, Valeria C, Pankaj T, Roverta G, et al. Activation of dendritic cells by tumor cell death. Oncoimmunology. 2012 Oct 1; 1(7): 1218-1219. doi: 10.4161/onci.20428 PMID: 23170286
6. Fucikova J, Kralikova P, Fialova A, Brtnicyy T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011 Jul 15; 71(14): 4821-4833. doi: 10.1158/0008-5472.CAN-11-0950 PMID: 21602432
7. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010 Jun 15; 16(12): 3100-3104. doi: 10.1158/1078-0432.CCR-09-2891 PMID: 20421432
8. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009 Mar 4; 28(5): 578-590. doi: 10.1038/emboj.2009.1 PMID: 19165151
9. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007 Jan; 13(1): 54-61. doi: 10.1038/nm1523 PMID: 17187072
10. Tandon VK, Yadav DB, Chaturvedi AK, Shukla PK. Synthesis of (1,4)-naphthoquinono-[3,2-c]-1H-pyrazoles and their (1,4)-naphthohydroquinone derivatives as antifungal, antibacterial, and anticancer agents. Bioorg Med Chem Lett. 2005 Jul 1; 15(13): 3288-3291. doi: 10.1016/j.bmcl.2005.04.066 PMID: 15913995
11. Yolanda T. P, Nathan L. D. Quinolinequinones.V. 6-Chloro-and 7-Chloro-5,8-quinolinequinones. J Am Chem Soc. 1960 Mar 5; 82(5): 1155-116.
12. Giorgi-renault S, Renault J, Baron M., Servolles P, Paoletti C, Cros S. Heterocyclic quinones : Synthesis and antitumoral effects of 5,10-benzo[g]quinoxalinediones and aza analogs. Eur J Med Chem. 1985; 20(2): 144-148.
13. Garuti L, Roberti M, Pizzirani D. Nitrogen-containing heterocyclic quinines: A class of potential selective antitumor agents. Mini Rev Med Chem. 2007 May; 7(5): 481-489. PMID: 17504183
14. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007 Sep; 27(5): 591-608. doi: 10.1002/ med.20095 PMID: 17019678
15. Martínez R, Chacón-García L. The search of DNA-intercalators as antitumoral drugs: What it worked and what did not work. Curr Med Chem. 2005; 12(2): 127-151. PMID: 15638732
16. Ryu CK, Lee SY, Kim NY, Hong JA, Yoon JH, Kim A. Synthesis and antifungal evaluation of 6-hydroxy- 1H-carbozole-1,4(9H)-diones. Bioorg Med Chem Lett. 2011 Jan 1; 21(1): 427-430. doi: 10.1016/j. bmcl.2010.10.124 PMID: 21075635
17. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005 Apr; 5(4): 331-342. doi: 10.1038/nri1594 PMID: 15803152
18. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets. 2006 Mar; 6(2) 107-121. PMID: 16529541
19. Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer. 2006 Apr 7; 5-15.
20. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, et al. Activation of Stat3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006 Jun; 15(6): 1445-1451. PMID: 16685378
21. Cumaraswamy AA, Todic A, Resetca D, Minden MD, Gunning PT. Inhibitors of Stat5 protein signaling. Med Chem Commun. 2012; 3: 22-27.
22. Hreggvidsdóttir HS, Lundberg AM, Aveberger AC, Klevenvall L, Andersson U, Harris HE. High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med. 2012 Mar 27; 18(1): 224-230.
23. Rani A, Murphy JJ. STAT5 in cancer and immunity. J Interferon Cytokine Res. 2016 Apr; 36(4):226-237. doi: 10.1089/jir.2015.0054 PMID: 26716518
24. Ioannis G, Nikolaos N, John S. STAT3 signaling in cancer. J Cancer Ther. 2015; 6: 709-726.